Abstract: The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.

Abstract: An on site bioremediation system that delivers logarithmically growing, active microorganisms from the culture vessel directly to the biodegradable waste to be metabolized is disclosed. The system includes a controller, culture vessel and separate containers of stock microorganisms and nutrient medium. The periodic or continuous addition of stock microorganisms and fresh nutrient media is controlled by a computer. After a particular cell density is reached, the active, logarithmically growing microorganisms flow out of the system to the waste site on a periodic or continuous basis.

Abstract: Mixed bacterial compositions minimally contain a mixed population of bacteria including at least one species of Nitrosomonas capable of converting ammonia to nitrite, at least one species of Nitrobacter capable of converting nitrite to nitrate, at least one species of Pseudomonas capable of converting nitrate to nitrite and capable of metabolizing urea, and at least one species of Enterobacter capable of metabolizing bacterial waste products and fermenting lactose. The ability of these aforementioned bacteria to metabolize the odor; and partially decompose the waste material producing the odor is enhanced by the addition of an acclimated mixed bacterial culture to the mixed bacterial composition containing the aforementioned species of Nitrosomonas, Nitrobacter, Pseudomonas, and Enterobacter. The acclimated mixed bacterial culture includes at least one and up to four different species or strains of Pseudomonas, at least one species of Acinetobacter, and at least one species of Enterobacter.

Abstract: DNA sequences of the EBV genome coding for EBV-related antigens as well as the EBV-related antigens, fusion proteins containing the EBV-related antigens, recombinant DNA molecules containing the DNA sequences, cells containing the recombinant DNA molecules, processes for producing EBV-related antigens, and diagnostic and pharmaceutical compositions are disclosed.